# PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval

> **NCT06196580** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Gout and Hyperuricemia

## Interventions

- **DRUG:** repaglinide; midazolam; SHR4640
- **DRUG:** repaglinide; midazolam; SHR4640; SHR4640 placebo
- **DRUG:** repaglinide; midazolam; SHR4640 placebo

## Key facts

- **NCT ID:** NCT06196580
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-04
- **Primary completion:** 2024-02-16
- **Final completion:** 2024-02-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196580, "PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06196580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*